Opioid Utilization and Health-Care Costs among Patients with Diabetic Peripheral Neuropathic Pain Treated with Duloxetine vs. Other Therapies

Pain Practice

Volumn 11, Issue 1, 2011, Pages 48-56

  Wu, Ning ^a   Chen, Shih Yin ^a   Hallett, Lindsay A ^a   Boulanger, Luke ^a   Fraser, Kimberly A ^a   Patel, Chintan K ^b   Zhao, Yang ^b  

^a Formerly Abt Bio Pharma Solutions Inc   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

Diabetic neuropathy; Health care costs; Opioids; Painful

Indexed keywords

DULOXETINE; GABAPENTIN; MORPHINE; OPIATE; PREGABALIN; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DIABETIC NEUROPATHY; DRUG USE; DRUG UTILIZATION; FEMALE; HEALTH CARE COST; HEALTH INSURANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NEUROPATHIC PAIN; PATIENT CARE; PRESCRIPTION; RETROSPECTIVE STUDY;

EID: 78651468374     PISSN: 15307085     EISSN: 15332500     Source Type: Journal    
DOI: 10.1111/j.1533-2500.2010.00392.x     Document Type: Article

References (28)

1. Argoff CE, Cole BE, Fishbain DA, Irving GA. Diabetic peripheral neuropathic pain: clinical and quality-of-life issues. Mayo Clin Proc. 2006;81:S3-S11.
2. Galer BS, Gianas A, Jensen MP. Painful diabetic polyneuropathy: epidemiology, pain description, and quality of life. Diabetes Res Clin Pract. 2000;47:123-128.
3. Boulton AJ. Management of diabetic peripheral neuropathy. Clin Diabetes. 2005;23:9-15.
4. Boulton AJ, Malik RA, Arezzo JC, Sosenko JM. Diabetic somatic neuropathies. Diabetes Care. 2004;27:1458-1486.
5. Benbow SJ, Wallymahmed ME, MacFarlane IA. Diabetic peripheral neuropathy and quality of life. Q J Med. 1998;91:733-737.
6. Gore M, Brandenburg NA, Hoffman DL, et al. Burden of illness in painful diabetic peripheral neuropathy: the patients' perspectives. J Pain. 2006;7:892-900.
7. Stewart WF, Ricci JA, Chee E, et al. Lost productive time and costs due to diabetes and diabetic neuropathic pain in the US workforce. J Occup Environ Med. 2007;49:672-679.
8. Gore M, Brandenburg NA, Dukes E, et al. Pain severity in diabetic peripheral neuropathy is associated with patient functioning, symptom levels of anxiety and depression, and sleep. J Pain Symptom Manage. 2005;30:374-385.
9. Jude EB, Jacob K. Managing painful neuropathy in diabetes. Pol Arch Med Wewn. 2008;118:260-261.
10. Candrilli SD, Davis KL, Kan HJ, et al. Prevalence and the associated burden of illness of symptoms of diabetic peripheral neuropathy and diabetic retinopathy. J Diabetes Complications. 2007;21:306-314.
11. Argoff CE, Backonja MM, Belgrade MJ, et al. Consensus guidelines: treatment planning and options. Diabetic peripheral neuropathic pain. Mayo Clin Proc. 2006;81:S12-S25.
12. Diabetic peripheral neuropathic pain: consensus guidelines for treatment. J Fam Pract. 2006;55(suppl):3-19.
13. Wu EQ, Birnbaum HG, Mareva MN, et al. Cost-effectiveness of duloxetine versus routine treatment for U.S. patients with diabetic peripheral neuropathic pain. J Pain. 2006;7:399-407.
14. Wu N, Chen S, Boulanger L, et al. Duloxetine compliance and its association with healthcare costs among patients with diabetic peripheral neuropathic pain. J Med Econ. 2009;12:192-202.
15. Jensen TS, Backonja MM, Hernandez JS, et al. New perspectives on the management of diabetic peripheral neuropathic pain. Diab Vasc Dis Res. 2006;3:108-119.
16. Benyamin R, Trescot AM, Datta S, et al. Opioid complications and side effects. Pain Physician. 2008;11:S105-S120.
17. Robinson-Papp J, Simpson DM. Safety profile of treatment in diabetic peripheral neuropathic pain. Pain Med. 2007;8:S43-S49.
18. Boulanger L, Zhao Y, Foster TS, et al. Impact of comorbid depression or anxiety on patterns of treatment and economic outcomes among patients with diabetic peripheral neuropathic pain. Curr Med Res Opin. 2009;25:1763-1773.
19. Bureau of Labor Statistics. Consumer price index. (accessed 20 January 2008).
20. Sullivan MD, Edlund MJ, Fan MY, et al. Trends in use of opioids for non-cancer pain conditions 2000-2005 in commercial and Medicaid insurance plans: the TROUP study. Pain. 2008;138:440-449.
21. Braden JB, Fan MY, Edlund MJ, et al. Trends in use of opioids by noncancer pain type 2000-2005 among Arkansas Medicaid and HealthCore enrollees: results from the TROUP study. J Pain. 2008;9:1026-1035.
22. Afifi AA, Kotlerman JB, Ettner SL, Cowan M. Methods for improving regression analysis for skewed continuous or count responses. Ann Rev Public Health. 2007;28:95-111.
23. McCullagh P, Nelder JA. Generalized Linear Models. 2nd ed. London: Chapman and Hall; 1989.
24. Efron B, Tibhirani R. An Introduction to the Bootstrap. New York: Chapman and Hall; 1993.
25. Gilson AM, Ryan KM, Joranson DE, Dahl JL. A reassessment of trends in the medical use and abuse of opioid analgesics and implications for diversion control: 1997-2002. J Pain Symptom Manage. 2004;28:176-188.
26. Barrett AM, Lucero MA, Le T, et al. Epidemiology, public health burden, and treatment of diabetic peripheral neuropathic pain: a review. Pain Med. 2007;8:S50-S62.
27. Boulton AJ. Treatment of symptomatic diabetic neuropathy. Diabetes Metab Res Rev. 2003;19:516-521.
28. Currie CJ, Poole CD, Woehl A, et al. The financial costs of healthcare treatment for people with Type 1 or Type 2 diabetes in the UK with particular reference to differing severity of peripheral neuropathy. Diabet Med. 2007;24:187-194.